Ronald Stafford Watts
Directeur/Membre du Conseil chez Wenkart Foundation
Profil
Ronald Stafford Watts is currently the Director at Wenkart Foundation and a Non-Executive Director at Biosceptre International Ltd.
He previously worked as a Non-Executive Director at Biosceptre (Aust) Pty Ltd.
and as a Non-Executive Director at Energy Action Ltd.
from 2003 to 2017.
He holds a doctorate degree from the University of Cambridge and an undergraduate degree from The University of New South Wales.
Postes actifs de Ronald Stafford Watts
| Sociétés | Poste | Début |
|---|---|---|
| Wenkart Foundation | Directeur/Membre du Conseil | - |
Biosceptre International Ltd.
 Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Directeur/Membre du Conseil | - |
Anciens postes connus de Ronald Stafford Watts
| Sociétés | Poste | Fin |
|---|---|---|
| ENERGY ACTION LIMITED | Président | 12/11/2015 |
Biosceptre (Aust) Pty Ltd.
 Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Directeur/Membre du Conseil | - |
Formation de Ronald Stafford Watts
| University of Cambridge | Doctorate Degree |
| The University of New South Wales | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENERGY ACTION LIMITED | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
| Wenkart Foundation | |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |